Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System

Mootz, Marilyn L; Britt, Rachel S; Mootz, Allison; Lee, Grace C.; Reveles, Kelly R.; Evoy, Kirk E.; Teng, Chengwen; Frei, Christopher R.

doi:10.1080/21548331.2019.1676540

Cited by 3 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mootz et al's (45) retrospective comparative effectiveness study included adults hospitalized with sepsis who received ceftaroline or daptomycin within 14 days of hospital admission. Patients treated with ceftaroline were less likely to experience readmission at 30 days (25 vs. 37%, P = 0.06), 60 days (27 vs. 44%, P = 0.008) and 90 days (28 vs. 46%, P = 0.01) compared to those treated with daptomycin (45). Moreover, the ceftaroline group showed a lower in-hospital mortality rate (7 vs. 12%, P = 0.4) at 30 days (3 vs. 9%, P = 0.1), 60 days (6 vs. 12%, P = 0.2), and 90 days (7 vs. 15%, P = 0.1) vs. the comparator (45).…”

Section: Ceftarolinementioning

confidence: 96%

“…The US Food and Drug Administration (FDA) approved a label expansion for the treatment of S. aureus bacteraemia associated with SSTIs in adults in 2015 and in the pediatric population in 2016 (32). The literature regarding the bacteraemic cohorts of patients treated with ceftaroline (alone or in combination) is growing and has been mostly comprised of subjects with a diagnosis of either persistent bacteraemia or MRSA bacteraemia that is not susceptible to vancomycin or daptomycin (32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47). Persistent bacteraemia (with or without a known focus of infections) is not an uncommon finding, which may be associated with increased mortality and morbidity, and refers to blood cultures that were positive within the same infectious episode and on different days (33,34) 34) multicenter observational study of 211 patients (33).…”

Section: Ceftarolinementioning

confidence: 99%

See 1 more Smart Citation

Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective

2021

View full text Add to dashboard Cite

In past decade, cephalosporins have developed significantly, and data regarding novel cephalosporins (i.e., ceftobiprole, ceftaroline, ceftolozane/tazobactam, ceftazidime/avibactam, and cefiderocol) within septic and bacteremic subjects are rising. These compounds generally offer very promising in vitro microbiological susceptibility, although the variability among gram-negative and -positive strains of different cohorts is noticed in the literature. We require further pharmacological data to measure the best dose in order to prevent sub-therapeutic drug levels in critically ill patients. These new compounds in theory are the sparing solution in the Enterobacteriales infection group for different antimicrobial classes such as aminoglycosides notably within endovascular and GNB-bacteremias, as well as colistin and carbapenem-sparing strategies, favoring good safety profile molecules. Moreover, new cephalosporins are the basis for the actual indications to open up new and exciting prospects for serious infections in the future. In future, patients will be addressed with the desirable approach to sepsis and serious infections in terms of their clinical situation, inherent features of the host, the sensitivity profile, and local epidemiology, for which evidence of the use of new cephalosporin in the treatment of severe infections will fill the remaining gaps.

show abstract

Section: Ceftarolinementioning

confidence: 96%

Section: Ceftarolinementioning

confidence: 99%

Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective

2021

View full text Add to dashboard Cite

show abstract

“…One of the main drawbacks of β-lactams in Staphylococcus aureus bacteremia (SAB) treatments is the absence of MRSA action [ 31 , 32 , 33 , 34 ]. Currently, ceftaroline is the only β-lactam antibiotic used for MRSA bacteremia and this is off-label with insufficient clinical evidence to provide optimal dose guidance [ 37 , 38 ].…”

Section: Introductionmentioning

confidence: 99%

Ceftobiprole Perspective: Current and Potential Future Indications

et al. 2021

View full text Add to dashboard Cite

Ceftobiprole combines an excellent spectrum for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) pathogens, with a low/medium MDR risk, and the β-lactams’ safety in frail patients admitted to the hospital in internal medicine wards which may be at high risk of adverse events by anti-MRSA coverage as oxazolidinones or glycopeptides. We aimed to report the available evidence regarding ceftobiprole use in pneumonia and invasive bacterial infections, shedding light on ceftobiprole stewardship. The clinical application and real-life experiences of using ceftobiprole for bloodstream infections, including infective endocarditis, are limited but nevertheless promising. In addition, extended-spectrum ceftobiprole activity, including Enterococcus faecalis, Enterobacteriaceae, and Pseudomonas aeruginosa, has theoretical advantages for use as empirical therapy in bacteremia potentially caused by a broad spectrum of microorganisms, such as catheter-related bacteremia. In the future, the desirable approach to sepsis and severe infections will be administered to patients according to their clinical situation, the intrinsic host characteristics, the susceptibility profile, and local epidemiology, while the “universal antibiotic strategy” will no longer be adequate.

show abstract

Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future

Bavaro,

Belati,

Bussini

et al. 2023

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care System

Cited by 3 publications

References 21 publications

Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective

Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective

Ceftobiprole Perspective: Current and Potential Future Indications

Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future

Contact Info

Product

Resources

About